To evaluate the impact of circulating immunosuppressive cells in (R/M) HNSCC patients, the levels of Treg subsets (total, resting, active, non-suppressive (ns) and CD137+) were evaluated in the blood of patients before the beginning of immunotherapy (T0) by flow cytometry. This evidence concerns the gene TNFRSF9 and head and neck squamous cell carcinoma.